×
Download Brochure Image

Next-Generation Immunotherapies for Solid Tumors

Commercializing breakthrough immune-oncology therapeutics is becoming increasingly challenging due to funding limitations, high cost and attrition rates in the clinic, regulatory uncertainties, persistent therapeutic safety and efficacy concerns, and a general lack of understanding of basic biology guiding research in this space. As we develop the 2025 conference program, we are struck by the fact that, despite these challenges, there remains a strong desire to continue to find effective therapeutics for solid tumors. The 13th Annual 2025 Immuno-Oncology Summit showcases successes in preclinical and clinical studies grounded in a deep understanding of biology. Coverage spans solid tumor innovations, including bi/multispecific antibodies, antibody-drug conjugates (ADCs), allogenic and in vivo CAR-Ts, TILs, TCRs, Tregs, multiple cell therapies working together, the tumor microenvironment, innate immunity, gamma delta T cells, NK cells, organoid modeling, data science, and machine learning. The program also explores autoimmunity as a critical and complementary area of focus.

Register Now
Final Agenda Image
Present a Research Poster
Sponsor and Exhibit

2025 Plenary Session

Off-the-Shelf Allogeneic CAR T Therapy in the Treatment of Severe Autoimmune Diseases

Biao Zheng, PhD

Biao Zheng, PhD
CEO, BRL Medicine


PANEL DISCUSSION: Advancing Immunotherapy: Strategies for Preventing Attrition

Rakesh Dixit, PhD

Moderator:
Rakesh Dixit, PhD, DABT
President & Founder, Bionavigen Oncology, LLC and Regio Biosciences

Carter Caldwell, MBA

Carter Caldwell, MBA
Co-Investment Program Director, University of Pennsylvania

Karen Chagin, MD

Karen Chagin, MD
Senior Vice President, Early Stage Development, Adaptimmune

Margery Ma, PhD

Margery Ma, PhD
Principal Consultant, NonClinical Regulatory Affairs, Eliquent Life Sciences


PANEL DISCUSSION: Accelerating IO through Target Discovery

Tatiana Novobrantseva, PhD

Moderator:
Tatiana Novobrantseva, PhD, CSO
NextPoint Therapeutics

Vitalay Fomin, PhD

Vitalay Fomin, PhD
Co-Founder, Numenos AI

Shameer Khader, PhD

Shameer Khader, PhD
Executive Director, Global Head of Data Science, Data Engineering and Computational Biology, Sanofi

Kristen Meerbrey, PhD

Kristen Meerbrey, PhD
Director of Target Discovery, Therapeutic Innovation Center, Baylor College of Medicine

THANK YOU TO OUR 2025 SPONSORS

Corporate Support Sponsors:

IRBM Mispro Nona Biosciences Wuxi-Apptec

Sights and Scenes from Immuno-Oncology Summit

Connect With Us

MEETING SUGGESTIONS

For meeting questions or suggestions, please contact:

Nikki Cerniuk
Conference Producer
Cambridge Healthtech Institute
ncerniuk@healthtech.com

PARTNERING & SPONSORSHIP

For partnering and sponsorship info, please contact:

Phillip Zakim-Yacouby
Senior Business Development Manager
Cambridge Healthtech Institute
+1 781.247.1815
philzy@healthtech.com

MEDIA & ASSOCIATION

For media and association partnerships, please contact:

Christine Benners
Senior Marketing Manager
Cambridge Healthtech Institute
cbenners@healthtech.com